Intra-Cellular Therapies Inc. (ITCI)

8.28
NASDAQ : Health Technology
Prev Close 8.50
Day Low/High 8.19 / 8.55
52 Wk Low/High 6.75 / 20.08
Avg Volume 1.11M
Exchange NASDAQ
Shares Outstanding 55.17M
Market Cap 468.97M
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Noteworthy Wednesday Option Activity: ITCI, CMTL, LOW

Noteworthy Wednesday Option Activity: ITCI, CMTL, LOW

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Intra-Cellular Therapies Inc , where a total of 4,832 contracts have traded so far, representing approximately 483,200 underlying shares. That amounts to about 44.8% of ITCI's average daily trading volume over the past month of 1.1 million shares.

Interesting ITCI Put And Call Options For May 2020

Interesting ITCI Put And Call Options For May 2020

Investors in Intra-Cellular Therapies Inc saw new options become available this week, for the May 2020 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Intra-Cellular Therapies Announces Progression To Higher Dose Cohort In ITI-214 Translational Medicine Study In Patients With Heart Failure

Intra-Cellular Therapies Announces Progression To Higher Dose Cohort In ITI-214 Translational Medicine Study In Patients With Heart Failure

Data indicate ITI-214 at a dose of 30 mg is well tolerated with a favorable safety profile Study '104 now proceeding to a third cohort at a dose of 90 mg NEW YORK, Sept.

First Week Of ITCI January 2022 Options Trading

First Week Of ITCI January 2022 Options Trading

Investors in Intra-Cellular Therapies Inc saw new options begin trading this week, for the January 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 857 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Intra-Cellular Therapies Provides Lumateperone Regulatory Update

Intra-Cellular Therapies Provides Lumateperone Regulatory Update

FDA has informed the Company it has no plans to schedule an Advisory Committee Meeting Company has completed submission of non-clinical information previously agreed with FDA  NEW YORK, Sept.

ITCI January 2020 Options Begin Trading

ITCI January 2020 Options Begin Trading

Investors in Intra-Cellular Therapies Inc saw new options become available today, for the January 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 158 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Intra-Cellular Therapies Provides Corporate Update And Reports Second Quarter 2019 Financial Results

Intra-Cellular Therapies Provides Corporate Update And Reports Second Quarter 2019 Financial Results

NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies To Present At The Canaccord Genuity 39th Annual Growth Conference

Intra-Cellular Therapies To Present At The Canaccord Genuity 39th Annual Growth Conference

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies To Host Conference Call To Provide Regulatory Update Following Recent Meeting With FDA

Intra-Cellular Therapies To Host Conference Call To Provide Regulatory Update Following Recent Meeting With FDA

Agreement reached with FDA on submission of additional non-clinical information for NDA review of lumateperone for the treatment of schizophrenia Lumateperone PDUFA goal date extended three months to December 27, 2019 Conference call scheduled today at...

Intra-Cellular Therapies Provides Update On FDA Advisory Committee Meeting For Lumateperone For The Treatment Of Schizophrenia

Intra-Cellular Therapies Provides Update On FDA Advisory Committee Meeting For Lumateperone For The Treatment Of Schizophrenia

NEW YORK, July 23, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.

Intra-Cellular Therapies Becomes Oversold (ITCI)

Intra-Cellular Therapies Becomes Oversold (ITCI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of September 20th Options Trading For Intra-Cellular Therapies (ITCI)

First Week Of September 20th Options Trading For Intra-Cellular Therapies (ITCI)

Investors in Intra-Cellular Therapies Inc saw new options become available this week, for the September 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ITCI options chain for the new September 20th contracts and identified one put and one call contract of particular interest.

Noteworthy Wednesday Option Activity: ITCI, NR, ROG

Noteworthy Wednesday Option Activity: ITCI, NR, ROG

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Intra-Cellular Therapies Inc , where a total of 12,493 contracts have traded so far, representing approximately 1.2 million underlying shares. That amounts to about 94% of ITCI's average daily trading volume over the past month of 1.3 million shares.

Intra-Cellular Therapies Announces Positive Top-line Results From A Phase 3 Trial Of Lumateperone In Patients With Bipolar Depression

Intra-Cellular Therapies Announces Positive Top-line Results From A Phase 3 Trial Of Lumateperone In Patients With Bipolar Depression

Study 404 met its primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (p<0.

2 Attractive Biotechs With Key Study Outcomes on the Horizon

2 Attractive Biotechs With Key Study Outcomes on the Horizon

Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.

Intra-Cellular Therapies Appoints Karen Patruno Sheehy, Esq. As Senior Vice President, Chief Compliance Officer

Intra-Cellular Therapies Appoints Karen Patruno Sheehy, Esq. As Senior Vice President, Chief Compliance Officer

NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of Karen Patruno...

Noteworthy Friday Option Activity: ITCI, AMPE, LULU

Noteworthy Friday Option Activity: ITCI, AMPE, LULU

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Intra-Cellular Therapies Inc , where a total of 6,851 contracts have traded so far, representing approximately 685,100 underlying shares. That amounts to about 181.8% of ITCI's average daily trading volume over the past month of 376,855 shares.

Oversold Conditions For Intra-Cellular Therapies (ITCI)

Oversold Conditions For Intra-Cellular Therapies (ITCI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Noteworthy Tuesday Option Activity: ITCI, CUB, ASGN

Noteworthy Tuesday Option Activity: ITCI, CUB, ASGN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Intra-Cellular Therapies Inc , where a total of 3,885 contracts have traded so far, representing approximately 388,500 underlying shares. That amounts to about 114.2% of ITCI's average daily trading volume over the past month of 340,165 shares.

2 Biotech Names See Directors Direct Cash to Their Shares

2 Biotech Names See Directors Direct Cash to Their Shares

The stock purchases by the insiders are at companies developing treatments for breast cancer and schizophrenia.

Noteworthy Monday Option Activity: ITCI, IMMR, ANAB

Noteworthy Monday Option Activity: ITCI, IMMR, ANAB

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Intra-Cellular Therapies Inc , where a total of 11,210 contracts have traded so far, representing approximately 1.1 million underlying shares. That amounts to about 387.1% of ITCI's average daily trading volume over the past month of 289,560 shares.

Notable Wednesday Option Activity: ITCI, IRTC, EA

Notable Wednesday Option Activity: ITCI, IRTC, EA

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Intra-Cellular Therapies Inc , where a total volume of 1,775 contracts has been traded thus far today, a contract volume which is representative of approximately 177,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 55% of ITCI's average daily trading volume over the past month, of 322,435 shares.

Noteworthy Monday Option Activity: ITCI, SD, KODK

Noteworthy Monday Option Activity: ITCI, SD, KODK

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Intra-Cellular Therapies Inc , where a total of 6,450 contracts have traded so far, representing approximately 645,000 underlying shares. That amounts to about 200.1% of ITCI's average daily trading volume over the past month of 322,270 shares.

Noteworthy Monday Option Activity: ITCI, LOB, ULTI

Noteworthy Monday Option Activity: ITCI, LOB, ULTI

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Intra-Cellular Therapies Inc , where a total volume of 4,439 contracts has been traded thus far today, a contract volume which is representative of approximately 443,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 129.5% of ITCI's average daily trading volume over the past month, of 342,900 shares.

First Week Of ITCI March 15th Options Trading

First Week Of ITCI March 15th Options Trading

Investors in Intra-Cellular Therapies Inc saw new options become available this week, for the March 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ITCI options chain for the new March 15th contracts and identified one put and one call contract of particular interest.

First Week Of ITCI May 2019 Options Trading

First Week Of ITCI May 2019 Options Trading

Investors in Intra-Cellular Therapies Inc saw new options begin trading this week, for the May 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 228 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Two to Buy on the Dip

Two to Buy on the Dip

Talk of intensifying trade war is creating some bargains for investors.

First Week of November 16th Options Trading For Intra-Cellular Therapies (ITCI)

Investors in Intra-Cellular Therapies Inc saw new options become available this week, for the November 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 227 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.